177Lu-octreotate肽受体放射性核素治疗神经内分泌肿瘤的个体化剂量方案:P-PRRT试验初步结果
34例完成诱导疗程的患者中,中位累积肾脏吸收剂量22.1 Gy,中位累积最大肿瘤吸收剂量185.7 Gy;与模拟固定活度方案相比,85.3%患者累积最大肿瘤吸收剂量中位增加1.26倍。39例可评估患者中客观缓解(部分缓解)9例(23.1%),轻微缓解14例(35.9%),疾病稳定13例(33.3%),疾病进展3例(7.7%)。
要点
- 个体化PRRT可根据肾脏吸收剂量安全提高多数患者的肿瘤照射剂量。
- 34例完成诱导疗程者中位累积最大肿瘤吸收剂量185.7 Gy,较模拟固定方案中位增加1.26倍。
- 39例可评估患者中部分缓解9例(23.1%),胰腺NET患者13例中11例(84.6%)达部分或轻微缓解。
核心结论
- 个体化PRRT使多数患者能够安全地提高肿瘤照射剂量。
- 初步结果显示耐受性良好,与经验性固定活度方案相似。
- 缓解率令人鼓舞,尤其在胰腺来源的NET患者中。
研究设计与样本
- P-PRRT试验(NCT02754297)为前瞻性研究,纳入未接受过PRRT的进展期和/或症状性NET患者。
- 患者计划接受四周期177Lu-octreotate诱导治疗,采用定量SPECT/CT剂量学。
- 第一周期注射活度根据肾小球滤过率和体表面积个体化,后续周期根据既往肾脏Gy/GBq调整。
- 肾脏处方吸收剂量为23 Gy,显著肾或血液学损害时降低25-50%。
- 缓解者可接受巩固或维持周期,每周期肾脏处方剂量6 Gy;模拟经验性方案为每周期固定7.4 GBq并采用相同百分比降低。
主要发现
- 34例完成诱导疗程患者的中位累积注射活度为36.1 GBq(范围6.3-78.6 GBq)。
- 上述34例患者中位累积肾脏吸收剂量为22.1 Gy(范围8.3-24.3 Gy),中位累积最大肿瘤吸收剂量为185.7 Gy(范围15.2-443.1 Gy)。
- 与模拟固定活度诱导方案相比,累积最大肿瘤吸收剂量中位增加1.26倍(范围0.47-2.12倍),85.3%患者更高。
- 39例可评估患者中,最佳客观疗效为部分缓解9例(23.1%)、轻微缓解14例(35.9%)、疾病稳定13例(33.3%)、疾病进展3例(7.7%);胰腺NET患者13例中11例(84.6%)达部分或轻微缓解。
关键数值与推荐
- 肾脏处方吸收剂量为23 Gy,显著肾或血液学损害时降低25-50%。
- 巩固或维持周期每周期肾脏处方剂量为6 Gy。
- 模拟经验性方案固定注射活度为每周期7.4 GBq。
临床怎么用
- 对进展期或症状性NET患者,可基于定量SPECT/CT剂量学个体化调整177Lu-octreotate注射活度以给予肾脏处方吸收剂量。
- 治疗中需根据肾小球滤过率、体表面积及既往肾脏Gy/GBq调整活度,并在肾或血液学损害时降低肾脏处方剂量。
- 胰腺NET患者可能从个体化PRRT中获得较高缓解率,但需注意淋巴细胞减少的监测。
局限性
- 本文报告的是P-PRRT试验的初步结果。
- 完成诱导疗程并纳入剂量学分析的患者为34例,疗效可评估患者为39例。
- 与固定活度方案的比较为模拟而非随机对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Peptide receptor radionuclide therapy (PRRT) is mostly administered using a fixed injected activity (IA) per cycle. This empiric regime results in highly variable absorbed doses to the critical organs and undertreatment of the majority of patients. We conceived a personalized PRRT protocol in which the IA is adjusted to deliver a prescribed absorbed dose to the kidney, with the aim to safely increase tumour irradiation. We herein report on the initial results of our prospective study of personalized PRRT, the P-PRRT Trial (NCT02754297). METHODS: PRRT-naïve patients with progressive and/or symptomatic neuroendocrine tumour (NET) were scheduled to receive a four-cycle induction course of 177Lu-octreotate with quantitative SPECT/CT-based dosimetry. The IA was personalized according to the glomerular filtration rate and the body surface area for the first cycle, and according to the prior renal Gy/GBq for the subsequent cycles. The prescribed renal absorbed dose of 23 Gy was reduced by 25-50% in case of significant renal or haematological impairment. Responders were allowed to receive consolidation or maintenance cycles, for each of which 6 Gy to the kidney were prescribed. We simulated the empiric PRRT regime by fixing the IA at 7.4 GBq per cycle, with the same percentage reductions as above. Radiological, molecular imaging, biochemical, and quality of life responses, as well as safety, were assessed. RESULTS: Fifty-two patients underwent 171 cycles. In 34 patients who completed the induction course, a median cumulative IA of 36.1 (range, 6.3-78.6) GBq was administered, and the median cumulative kidney and maximum tumour absorbed doses were 22.1 (range, 8.3-24.3) Gy and 185.7 (range: 15.2-443.1) Gy respectively. Compared with the simulated fixed-IA induction regime, there was a median 1.26-fold increase (range, 0.47-2.12 fold) in the cumulative maximum tumour absorbed dose, which was higher in 85.3% of patients. In 39 assessable patients, the best objective response was partial response in nine (23.1%), minor response in 14 (35.9%), stable disease in 13 (33.3%) and progressive disease in three patients (7.7%). In particular, 11 of 13 patients (84.6%) with pancreatic NET had partial or minor response. The global health status/quality of life score significantly increased in 50% of patients. Acute and subacute side-effects were all of grade 1 or 2, and the most common were nausea (in 32.7% of patients) and fatigue (in 30.8% of patients) respectively. Subacute grade 3 or 4 toxicities occurred in less than 10% of patients, with the exception of lymphocytopenia in 51.9% of patients, without any clinical consequences however. No patient experienced severe renal toxicity. CONCLUSIONS: Personalized PRRT makes it possible to safely increase tumour irradiation in the majority of patients. Our first results indicate a favourable tolerance profile, which appears similar to that of the empiric regime. The response rates are promising, in particular in patients with NET of pancreatic origin.
引用
- Del Prete M, Buteau FA, Arsenault F, et al. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2018. PMID: 30506283. doi:10.1007/s00259-018-4209-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。